Compare
Camp4 Therapeutics Corp vs Marker Therapeutics, Inc. vs TherapeuticsMD, Inc. vs Xenetic Biosciences, Inc.
| Latest fiscal year | Camp4 Therapeutics Corp CAMP | Marker Therapeutics, Inc. MRKR | TherapeuticsMD, Inc. TXMD | Xenetic Biosciences, Inc. XBIO |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $3.50M | $3.55M | $3.02M | $2.98M |
| Revenue growth (YoY) | +436.5% | -46.2% | +71.6% | +19.0% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/m | -363.5% | -145.3% | -95.2% |
| Net margin | n/m | -343.0% | -18.8% | -90.1% |
| Net income | -$80.40M | -$12.16M | -$569.0K | -$2.68M |
| EPS (Diluted) | -$2.65 | -$0.79 | -$0.05 | -$1.58 |
| Operating cash flow | -$29.55M | -$12.01M | $2.45M | -$2.29M |
| Free cash flow | -$29.83M | n/a | n/a | n/a |
| Cash & equivalents | $109.52M | $16.07M | n/a | n/a |
| Total assets | $117.81M | $19.07M | $37.66M | $8.36M |
| Total liabilities | $70.10M | $2.27M | $10.78M | $968.0K |
| Shareholders' equity | $47.70M | $16.80M | $26.88M | $7.40M |
| Return on year-end equity | -168.5% | -72.4% | -2.1% | -36.2% |
| Shares outstanding | 51.90M | 16.70M | 11.57M | 2.29M |
Revenue, most recent five fiscal years
| Fiscal year | Camp4 Therapeutics Corp | Marker Therapeutics, Inc. | TherapeuticsMD, Inc. | Xenetic Biosciences, Inc. |
|---|---|---|---|---|
| Latest | $3.50M Ended 2025-12-31 | $3.55M Ended 2025-12-31 | $3.02M Ended 2025-12-31 | $2.98M Ended 2025-12-31 |
| 1 year earlier | $652.0K Ended 2024-12-31 | $6.59M Ended 2024-12-31 | $1.76M Ended 2024-12-31 | $2.50M Ended 2024-12-31 |
| 2 years earlier | $350.0K Ended 2023-12-31 | $3.31M Ended 2023-12-31 | $1.30M Ended 2023-12-31 | $2.54M Ended 2023-12-31 |
| 3 years earlier | n/a | $3.51M Ended 2022-12-31 | $69.96M Ended 2022-12-31 | $1.71M Ended 2022-12-31 |
| 4 years earlier | n/a | $1.24M Ended 2021-12-31 | $2.57M Ended 2021-12-31 | $1.16M Ended 2021-12-31 |